The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with NSCLC w...

Descripción completa

Detalles Bibliográficos
Autores principales: Brahmer, Julie R., Govindan, Ramaswamy, Anders, Robert A., Antonia, Scott J., Sagorsky, Sarah, Davies, Marianne J., Dubinett, Steven M., Ferris, Andrea, Gandhi, Leena, Garon, Edward B., Hellmann, Matthew D., Hirsch, Fred R., Malik, Shakuntala, Neal, Joel W., Papadimitrakopoulou, Vassiliki A., Rimm, David L., Schwartz, Lawrence H., Sepesi, Boris, Yeap, Beow Yong, Rizvi, Naiyer A., Herbst, Roy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048854/
https://www.ncbi.nlm.nih.gov/pubmed/30012210
http://dx.doi.org/10.1186/s40425-018-0382-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048854/
https://www.ncbi.nlm.nih.gov/pubmed/30012210
http://dx.doi.org/10.1186/s40425-018-0382-2

Ejemplares similares